arrow
R

Renato D. Lópes

Duke University
H指数:115
被引数:6.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Coated or chewable aspirin and a hybrid air pollution mitigation strategy in patients with atherosclerotic disease: rationale and design of the COATED-AIR randomized trial

包衣或咀嚼型阿司匹林及一种混合空气污染缓解策略在动脉粥样硬化患者中的应用:COATED-AIR随机试验的原理与设计

2026-09-230
OAAI
Antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation: an individual patient data network meta-analysis

房颤患者经皮冠状动脉介入治疗后的抗血栓治疗:一项个体患者数据网络荟萃分析

2026-08-300
OAAI
Recurrent myocardial infarction identified by centralized troponin review: Insights from the MINT trial

通过集中肌钙蛋白审查识别的复发性心肌梗死:MINT试验的启示

2026-08-010
PRE
The win ratio for evaluating edoxaban versus dalteparin for cancer-associated venous thromboembolism: an analysis of the randomized Hokusai VTE cancer trial

评估爱多沙班与达肝素治疗肿瘤相关性静脉血栓栓塞症的胜率比:一项随机okusai VTE cancer试验的分析

2025-12-190
OAAI
Prasugrel or ticagrelor monotherapy vs dual antiplatelet treatment after percutaneous coronary intervention in acute coronary syndromes: a landmark analysis from the NEOMINDSET trial

急性冠脉综合征经皮冠状动脉介入治疗后普拉格雷或替格瑞洛单药治疗与双联抗血小板治疗的比较: 来自NEOMINDSET试验的里程碑分析

2025-12-190
OA
Transfusion-related adverse events in patients with restrictive or liberal transfusion strategy. An analysis of the MINT trial

限制性或宽松性输血策略患者的输血相关不良事件。MINT试验分析

2025-11-260
OAAI
Sacubitril-Valsartan Versus Enalapril in Heart Failure Due to Chagas Disease: Primary Results of ANSWER-HF Randomized Trial

沙库巴曲-缬沙坦与依那普利在恰加斯病所致心力衰竭中的比较:ANSWER-HF随机试验的主要结果

JACC
IF0
2025-11-090
PRE
Reply to the letter regarding the article ‘Sacubitril/valsartan versus enalapril in chronic Chagas cardiomyopathy with heart failure: Baseline characteristics of the PARACHUTE-HF trial’

回复关于文章‘Sacubitril/valsartan versus enalapril in chronic Chagas cardiomyopathy with heart failure: Baseline characteristics of the PARACHUTE-HF trial’的信件

2025-10-140
PRE
Prevalence and factors associated with cardiometabolic multimorbidity: a cross-sectional study in older adults of the first Brazilian hypertension registry

心血管代谢多病共存的发生率及其相关因素:一项针对巴西高血压登记研究中老年人群的横断面研究

2025-10-010
OAAI
Overcoming Barriers to Developing and Implementing Novel Therapies for Hypertension

克服开发与实施新型高血压疗法的障碍

2025-10-010
PRE
Empagliflozin after myocardial infarction with or without diabetes and chronic kidney disease: Insights from EMPACT-MI

心力衰竭伴或不伴糖尿病和慢性肾脏病的患者接受心肌梗死后 empa gliflozin 治疗的疗效:来自 EMPACT-MI 的启示

2025-09-140
OAAI
Sacubitril/valsartan versus enalapril in chronic Chagas cardiomyopathy with heart failure: Baseline characteristics of the PARACHUTE-HF trial

沙库巴曲缬沙坦与依那普利在慢性恰加斯心肌病伴心力衰竭中的比较:PARACHUTE-HF试验的基线特征

2025-09-080
PRE
Cost-effectiveness of apixaban vs. aspirin for the reduction of thrombo-embolism in high-risk patients with device-detected atrial fibrillation: insights from the ARTESiA trial

阿哌沙班与阿司匹林在降低设备检测到心房颤动的高危患者血栓栓塞事件中的成本效益:ARTESiA试验的启示

2025-09-011
OAAI
Effects of Mavacamten on Cardiac Biomarkers in Nonobstructive Hypertrophic Cardiomyopathy

Mavacamten对非梗阻性肥厚型心肌病心脏生物标志物的影响

JACC
IF0
2025-08-270
PRE
Apixaban for stroke prevention in subclinical atrial fibrillation detected by an implantable cardiac monitor: a subgroup analysis of ARTESiA

阿哌沙班用于由植入式心脏监护仪检测到的亚临床房颤患者的卒中预防:ARTESiA研究的亚组分析

2025-08-050
PRE